Feasibility of Lecanemab Registry and Clinical Outcome Measures
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Lecanemab.
- Who it may be relevant to
- Registry conditions: Alzheimer Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Available FDA approved treatments for Alzheimer's disease (AD) temporary alleviate symptoms but have no bearing on overall disease progression. However, recent FDA approval of lecanemab (July 2023), a disease modifying therapy based on a phase 3 clinical trial demonstrated efficacy (cognitive) in persons with AD. Delaying the disease progression may impact not only the person living with dementia (PLWD), but also their Care Partners. It may provide the ability to achieve "life goals" as a family or may increase/reduce stress and burden on the family due to the complexity of the treatment regimen. Recent secondary analysis of this Phase 3 trial suggests quality of life showed less decline in PLWD and less increase in burden in Care Partners. The investigators propose to create a registry/database for persons living with dementia who receive lecanemab infusions at HealthPartners and their Care Partners. The investigators plan to test the feasibility of collecting outcomes data for specific patient and family focused outcomes, and outcomes that are typically not included in clinic. The outcome of this study will help in the overall goal of studying the impact of lecanemab in real-world settings in a larger cohort of PLWD and Care Partners.
Interventions
- Drug Lecanemab
Bi-weekly infusions of lecanemab \[exposure\].
Primary outcome measures
- Feasibility of enrollment [Time frame: 2 years]
- Feasibility of completing visits [Time frame: 3 months]
- Qualitative experience at 3 months [Time frame: 3 months]
- Qualitative experience at 12 months [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- PLWD who are eligible to receive Lecanemab infusion at our clinics.
- Care Partner who provides care for the PLWD who are eligible to receive Lecanemab infusion at our clinics.
- Age >=18 years for PLWD and their care partners
- Provides informed consent prior to participation.
Exclusion criteria
- Unable to read and speak English
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- HealthPartners Neuroscience Center — Saint Paul
Identifiers
NCT: NCT06285448 · A24-028